Intraoperative cell transplantation for congestive heart failure: experience in China.
Despite significant improvement in the management of congestive heart failure (CHF), it still is a major worldwide public health problem. Currently, cell-based regenerative medicine has been developed as a promising therapeutic option for patients with CHF. Considering the large and growing population, it is estimated that over 5 million patients in China may need such a cell-based therapy to replace or repair the damaged myocardium. Cardiac surgery has emerged as an important player in heart cell therapy in China in recent years. Here, we summarize our achievements in both preclinical and clinical studies of intraoperative cell transplantation, and present our understanding of future research in this attractive field.
Zhang
Hao
H
Research Center for Cardiac Regenerative Medicine, Ministry of Health, and Department of Cardiac Surgery, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wei
Ying-jie
YJ
Hu
Sheng-shou
SS
D000818:Animals; D016026:Bone Marrow Transplantation / Q000379:methods; D006348:Cardiac Surgical Procedures; D002470:Cell Survival; D017690:Cell Transplantation; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D007432:Intraoperative Period; D032448:Myoblasts, Skeletal / Q000637:transplantation; D009206:Myocardium / Q000166:cytology*